Article info

Download PDFPDF
Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis

Authors

  • Takayoshi Morita Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan PubMed articlesGoogle scholar articles
  • Kosuke Fujimoto Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan Department of Mucosal Immunology, School of Medicine, Chiba University, Japan Division of Innate Immune Regulation, Institute of Medical Science, International Research and Development Center for Mucosal Vaccines, The University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Yoshihito Shima Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan PubMed articlesGoogle scholar articles
  • Atsushi Ogata Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan Division of Allergy, Rheumatology and Connective Tissue Disease, NTT West Osaka Hospital, Osaka, Japan PubMed articlesGoogle scholar articles
  • Atsushi Kumanogoh Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Atsushi Ogata, Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan; atsushi.ogata.mc{at}west.ntt.co.jp
View Full Text

Citation

Morita T, Fujimoto K, Shima Y, et al
Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis

Publication history

  • Received September 10, 2017
  • Accepted September 11, 2017
  • First published September 22, 2017.
Online issue publication 
August 10, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.